A panel in Europe suggests approving a new use for Novartis' Cosentyx to treat a skin condition in teens.

Nov 13, 2026, 9:04 AM ETTrialRead the original at marketscreener.com

Good for NVS

Novartis' Cosentyx gained a European panel's recommendation for use in an adolescent skin condition. This advances a possible expansion, but final approval is not reported.

NVS · Novartis

AI read · Good for NVS

The AI's read

That recommendation could give Cosentyx another use in Europe and bring it to more patients. The source calls this progress, but does not report final approval or sales results, so the benefit is still potential.

Get alerts for NVS

Follow Novartis (NVS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NVS

Free on the App Store and Google Play, or on the web.